Arixa Pharmaceuticals, Inc.

Pharma companies should diversify by acquiring small biotechs developing antimicrobial and antifungal products to help address the problem of antimicrobial resistance (AMR), according to the foundatio

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol Seeks Novel Targets, Candidates

Arix Bioscience PLC 's ongoing search for quality science and value potential has prompted it to make its first Venture Investment in Public Equity (VIPE) with Australian listed Pharmaxis Ltd. , gain

Derived from Strategic Transactions , Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biophar